Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptide Bonds02:43

Peptide Bonds

82.9K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.9K
Internal Receptors01:31

Internal Receptors

74.6K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.6K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

110.9K
Overview
110.9K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

86.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.6K
Group Therapy01:26

Group Therapy

434
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
434

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a <sup>89</sup>Zr-based dosimetric approach for <sup>225</sup>Ac.

European journal of nuclear medicine and molecular imaging·2026
Same author

Chelator-Free Radiometal Labeling Inside Engineered Affibodies.

Angewandte Chemie (International ed. in English)·2026
Same author

Phase 1 Dose-Escalation Study of [<sup>225</sup>Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Challenges in tracer development for tumor microenvironment (TME) imaging.

European journal of nuclear medicine and molecular imaging·2026
Same author

La-[<sup>18/19</sup>F]fluoride complexes: a novel addition to the radiofluorination family.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a <sup>99m</sup>Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Related Experiment Video

Updated: Jan 31, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K

New Developments in Peptide Receptor Radionuclide Therapy.

Guillaume P Nicolas1, Alfred Morgenstern2, Margret Schottelius3

  • 1University Hospital Basel, University of Basel, Switzerland.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|December 22, 2018
PubMed
Summary

Peptide Receptor Radionuclide Therapy (PRRT) offers targeted radiation for neuroendocrine neoplasms. Radiotheranostics enhance treatment selection and efficacy by combining imaging and therapy.

Keywords:
G-protein coupled receptorsNeuroendocrinePeptidesRadionuclide Therapyalpha radiation therapybeta radiation therapytargeted radionuclide therapytheranostics

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.1K

Related Experiment Videos

Last Updated: Jan 31, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.1K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Chemistry

Background:

  • Peptide Receptor Radionuclide Therapy (PRRT) is a key treatment for metastatic neuroendocrine neoplasms.
  • PRRT utilizes radiolabeled peptides targeting specific molecular receptors on tumor cells.
  • The evolution of imaging companions led to radiotheranostics for improved patient selection and treatment.

Purpose of the Study:

  • To review the current landscape and future directions of Peptide Receptor Radionuclide Therapy.
  • To highlight the role of radiotheranostics in personalized cancer treatment.
  • To discuss the expanding targets beyond somatostatin receptors for PRRT.

Main Methods:

  • Review of established and emerging peptide-based radiopharmaceuticals.
  • Analysis of different radionuclide emitters (e.g., 177Lu, alpha emitters) used in PRRT.
  • Discussion of radioligands targeting receptors like CCK2, GRPR, NK1, and CXCR4.

Main Results:

  • Somatostatin receptor targeting remains a cornerstone of PRRT.
  • 177Lu is the predominant radionuclide for current PRRT applications.
  • Emerging radiotracers and alpha emitters show significant promise for advanced PRRT.

Conclusions:

  • PRRT is a vital theranostic approach for neuroendocrine tumors.
  • Expansion of targeted receptors and radionuclide choices broadens PRRT applications.
  • Continued research into novel radiopharmaceuticals will further refine personalized cancer therapy.